Thrombosis in end-stage renal disease
- PMID: 12753687
- DOI: 10.1046/j.1525-139x.2003.16048.x
Thrombosis in end-stage renal disease
Abstract
Although renal failure has classically been associated with a bleeding tendency, thrombotic events are common among patients with end-stage renal disease (ESRD). A variety of thrombosis-favoring hematologic alterations have been demonstrated in these patients. In addition, "nontraditional" risk factors for thrombosis, such as hyperhomocysteinemia, endothelial dysfunction, inflammation, and malnutrition, are present in a significant proportion of chronic dialysis patients. Hemodialysis (HD) vascular access thrombosis, ischemic heart disease, and renal allograft thrombosis are well-recognized complications in these patients. Deep venous thrombosis and pulmonary embolism are viewed as rare in chronic dialysis patients, but recent studies suggest that this perception should be reconsidered. Several ESRD treatment factors such as recombinant erythropoietin (EPO) administration, dialyzer bioincompatibility, and calcineurin inhibitor administration may have prothrombotic effects. In this article we review the pathogenesis and clinical manifestations of thrombosis in ESRD and evaluate the evidence that chronic renal failure or its management predisposes to thrombotic events.
Comment in
-
Thrombosis in end-stage renal disease.Semin Dial. 2004 Jan-Feb;17(1):71; author reply 71-2. doi: 10.1111/j.1525-139x.2004.17121.x. Semin Dial. 2004. PMID: 14717819 No abstract available.
Similar articles
-
Thrombosis and occlusion of vascular access in hemodialyzed patients.Semin Thromb Hemost. 2011 Nov;37(8):946-54. doi: 10.1055/s-0031-1297373. Epub 2011 Dec 23. Semin Thromb Hemost. 2011. PMID: 22198859 Review.
-
Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention.Am J Cardiovasc Drugs. 2004;4(3):139-49. doi: 10.2165/00129784-200404030-00001. Am J Cardiovasc Drugs. 2004. PMID: 15134466 Review.
-
Exhausting multiple hemodialysis access failures.Med Arch. 2014 Oct;68(5):361-3. doi: 10.5455/medarh.2014.68.361-363. Epub 2014 Oct 15. Med Arch. 2014. PMID: 25568574 Free PMC article.
-
Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients.Kidney Int. 2002 Nov;62(5):1757-63. doi: 10.1046/j.1523-1755.2002.00627.x. Kidney Int. 2002. PMID: 12371977
-
Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.Nephrol Dial Transplant. 2002;17 Suppl 5:32-7. doi: 10.1093/ndt/17.suppl_5.32. Nephrol Dial Transplant. 2002. PMID: 12091605 Review.
Cited by
-
Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro.BMC Nephrol. 2012 Sep 28;13:127. doi: 10.1186/1471-2369-13-127. BMC Nephrol. 2012. PMID: 23020133 Free PMC article. Clinical Trial.
-
Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm.J Thromb Thrombolysis. 2005 Jun;19(3):215-7. doi: 10.1007/s11239-005-1858-8. J Thromb Thrombolysis. 2005. PMID: 16082611 No abstract available.
-
Increased Thrombogenicity in Chronic Renal Failure in a Rat Model Induced by 5/6 Ablation/Infarction.Yonsei Med J. 2018 Aug;59(6):754-759. doi: 10.3349/ymj.2018.59.6.754. Yonsei Med J. 2018. PMID: 29978612 Free PMC article.
-
Comparison of long-term clinical outcomes among zotarolimus-, everolimus-, and biolimus-eluting stents in acute myocardial infarction patients with renal impairment.Cardiol J. 2023;30(3):440-452. doi: 10.5603/CJ.a2021.0099. Epub 2021 Sep 7. Cardiol J. 2023. PMID: 34490605 Free PMC article.
-
Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts.J Am Soc Nephrol. 2016 Apr;27(4):1254-64. doi: 10.1681/ASN.2015010068. Epub 2015 Oct 9. J Am Soc Nephrol. 2016. PMID: 26453609 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials